Baird analyst Timothy Wojs maintains Acuity Brands (NYSE:AYI) with a Outperform and raises the price target from $188 to $190.
Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine
Oragenics Inc (NYSE: OGEN) has
Baird Maintains Outperform on Acuity Brands, Raises Price Target to $190
Baird analyst Timothy Wojs maintains Acuity Brands (NYSE:AYI) with a Outperform and raises the price target from $188 to $190.
Related Posts
Global Medical REIT Q2 FFO $0.22 Up From $0.19 YoY, Sales $28.20M Miss $28.63M Estimate
Global Medical REIT (NYSE:GMRE) reported quarterly earnings of $0.22 per share. This is a 15.79 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of